Tech Company Financing Transactions
Neothetics Funding Round
Neothetics, based in San Diego, secured $6.7 million from RusnanoMedInvest, Andrea Holdings International and Mirae Asset Venture Investment.
Transaction Overview
Company Name
Announced On
7/22/2013
Transaction Type
Venture Equity
Amount
$6,700,000
Round
Series C
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9191 Towne Centre Dr. 400
San Diego, CA 92122
USA
San Diego, CA 92122
USA
Phone
Website
Email Address
Overview
Neothetics is a clinical-stage specialty pharmaceutical company developing therapeutics addressing both lifestyle and medical indications in aesthetic medicine and ophthalmology. Our lead product candidate, LIPO-202, is a first-in-class injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Scientific Officer
Kenneth Locke
VP - Bus. Development
Fara Berkowitz
VP - Finance
Susan Knudson
VP - Regulatory Affairs
Maria Feldman
Browse more venture capital transactions:
Prev: 7/22/2013: KeepSafe venture capital transaction
Next: 7/22/2013: VelociData venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. VC transactions reported here are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs